N 6 -methylation of 2'-O-methyladenosine (Am) in RNA occurs in eukaryotic cells to generate N 6 ,2'-O-dimethyladenosine (m6Am). Identification of the methyltransferase responsible for m6Am catalysis has accelerated studies on the function of m6Am in RNA processing. While m6Am is generally found in the first transcribed nucleotide of mRNAs, the modification is also found internally within U2 snRNA. However, the writer required for catalyzing internal m6Am formation had remained elusive. By sequencing transcriptome-wide RNA methylation at single-base-resolution, we identified human METTL4 as the writer that directly methylates Am at U2 snRNA position 30 into m6Am. We found that METTL4 localizes to the nucleus and its conserved methyltransferase catalytic site is required for U2 snRNA methylation. By sequencing human cells with overexpressed Mettl4, we determined METTL4's in vivo target RNA motif specificity. In the absence of Mettl4 in human cells, U2 snRNA lacks m6Am thereby affecting a subset of splicing events that exhibit specific features such as overall 3' splice-site weakness with certain motif positions more affected than others. This study establishes that METTL4 methylation of U2 snRNA regulates splicing of specific pre-mRNA transcripts.
Introduction
N 6 -methylation of deoxyadenosine affects the biophysical properties of the modified DNA and also regulates genomic processes (1, 2) . Likewise, N 6 -methylation of adenosine generates RNA modifications that regulate the expression and metabolism of the host RNA without changing the underlying sequence (3) . One resultant RNA modification is N 6 -methyladenosine (m6A) that is found internally within various RNA species including mRNAs and rRNAs (4) (5) (6) (7) . Each of the several identified m6A methyltransferases (writers) that catalyze N 6 -methylation of adenosine have different target sequence specificities. For example, METTL3 catalyzes N 6methylation of DRACH to give DRm6ACH (D=A/G/U, R=A/G, H=A/C/U) (4, 5, 8, 9) .
METTL3 also functions in a complex with co-factors including METTL14, WTAP, KIAA1429 and RBM15/RBM15B (10) (11) (12) (13) (14) . This complex mostly targets mRNAs in the region proximal to the stop codon. Another m6A writer is METTL16 that methylates 'UACAGAGAA' to give 'UACm6AGAGAA'. Besides U6 snRNA, METTL16 also targets the Mat2a 3'UTR (15) . Finally, ZCCHC4 and METTL5 have been identified as the writers responsible for m6A catalysis in 18S rRNA and 28S rRNA respectively (16) (17) (18) .
Adenosine N 6 -methylation of 2'-O-methyladenosine (Am) results in the RNA modification N 6 ,2'-O-dimethyladenosine (m6Am) that is found in the first transcribed nucleotide adjacent to the RNA methylguanosine cap ( Figure S1A ) (19, 20) . Given its predicted N 6 -methyladenine methyltransferase domain and its interaction with the phosphorylated C-terminal tail of RNA polymerase II during RNA transcription, PCIF1 was a strong candidate as a N 6 -methyladenine writer (21, 22) . Subsequently, PCIF1 was established as the writer responsible for the N 6 -methylation of Am at the transcriptional start site (TSS) to generate m6Am (23) (24) (25) (26) (27) . This facilitated the characterization of TSS-associated m6Am as a regulator of mRNA resistance to DCP2-mediated decapping, and potentially mRNA translation and cell growth (19, 23, 25, 26) .
Besides TSS-associated m6Am, m6Am sites have also been mapped to internal RNA sites, specifically at U2 snRNA position 30 (20, 28) . The functional importance of m6Am in U2 snRNA was not well-characterized, likely because the writer responsible for methylating U2 snRNA Am30 was previously unknown. In our work here, we utilize a primarily sequencing approach to establish methyltransferase-like 4 (Mettl4) as the U2 snRNA m6Am writer. By overexpressing Mettl4, we uncovered both the in vivo target sequence preference of METTL4 and its ability to catalyze m6Am formation internally within mRNAs. Finally, by knocking out Mettl4 from cells, we demonstrate that the resulting loss of U2 snRNA m6Am perturbs splicing of target mRNAs with distinctive features such as weak 3' splice sites.
Results

U2 snRNA m6Am is absent in Mettl4-KO cells
Mettl4 is one of a diverse family of proteins that are homologous to the MT-A70 subunit of the m6A writer Mettl3 (29) . In order to assess Mettl4 as a potential writer, we performed m6A-Crosslinking-Exonuclease-sequencing (m6ACE-seq), which is capable of quantitatively mapping precise N 6 -methyladenine methylomes in the form of m6A or m6Am ( Figure S1A ) (27) . Comparison of the RNA methylomes between wildtype (WT) and Mettl4-KO HEK293T cells revealed a single site that exhibited almost 70 fold reduced relative methylation level (RML) in the absence of METTL4 ( Figure 1A,1B) . The single-base-resolution of m6ACE-seq allowed us to map this site to position 30 of U2 snRNA ( Figure 1C ). To verify that this METTL4-dependent adenosine methylation is located within U2 snRNA, we isolated various snRNAs for anti-m6A dot blotting ( Figure S1B ). As expected, we detected an RNA methylation signal specific only to WT U2 snRNA but not in Mettl4-KO U2 snRNA or any U1 snRNA ( Figure 1D ).
Since the anti-m6A antibody is not able to distinguish between the structurally similar m6A and m6Am modifications ( Figure S1A ), isolated U2 snRNA was digested and subjected to nucleoside high performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS) to verify the identity of the RNA modification within U2 snRNA. While there were no appreciable m6A levels in U2 snRNA, we instead found that the majority of Am are in the N 6methylated m6Am form ( Figure 1E , S1C, S1D). More importantly, m6Am was not detected in Mettl4-KO U2 snRNA ( Figure 1E , S1C). We note that the HPLC-MS/MS m6Am signal was derived internally from U2 snRNA as we did not use any decapping enzyme in digesting U2 snRNA, which would prevent the quantification of any cap-adjacent RNA nucleotide. Furthermore, previous and current RNA methylomes have demonstrated that U2 snRNA lacks a TSS-associated adenosine N 6 -methylation ( Figure 1C ) (27) . Altogether, this demonstrates that METTL4 is necessary for m6Am formation within U2 snRNA. N 6 -methylation of U2 snRNA-internal Am requires the METTL4 DPPW catalytic motif METTL4 can either directly catalyze the N 6 -methylation of Am or act as an indirect co-factor to the actual catalytic writer. To investigate METTL4's role in RNA methylation, we expressed and purified recombinant C-terminal-3x-FLAG-tagged human METTL4 (METTL4 WT ) (Figure 2A , S2A). Incubation of METTL4 WT with a RNA oligonucleotide matching the 35nt 5' end of U2 snRNA (U2-Am30, Figure 2B , Table   1 ) generated a N 6 -methyladenosine signal detectable via anti-m6A dot blotting ( Figure 2C ). Using HPLC-MS/MS, we verified this methylated signal as m6Am and not m6A ( Figure 2D ). Additionally, METTL4 contains a 'DPPW' motif, which are catalytic residues required for methyltransferase activity (29) . Therefore, we mutated the METTL4 'DPPW' to 'APPA' to generate a catalytically-dead METTL4 (METTL4 CD , Figure 2A , S2A). Using the same in vitro methylation assay, we found that loss of the 'DPPW' catalytic site in METTL4 CD abrogates its ability to methylate RNA Am into m6Am ( Figure 2C, 2D ). This demonstrates that human METTL4 directly catalyzes the N 6 -methylation of Am to m6Am in vitro.
Given the structural similarity between Am and A, we next tested if METTL4 is also able to methylate A into m6A ( Figure S1A ). We subjected a similar U2 snRNA-based RNA substrate with the single Am replaced with A (U2-A30, Table 1 ) to in vitro methylation by METTL4 WT (Figure 2B ). This led to quantifiable m6A signals, albeit at a lower level than that of METTL4 WT in vitro methylation of U2-Am30 ( Figure S2B ).
Expectedly, this methylation activity was absent for METTL4 CD . Both U2-A30 and U2-Am30 contain adenosine in 2 adenosines in 'AAG' motifs but only adenosine in position 30 within the 'CAAGUG' context is N 6 -methylated by METTL4 ( Figure 2B -2D, S2B). This suggests A in the middle of 'CAAGUG' to be METTL4's target substrate sequence, with a preference for Am over A for adenine-N 6 -methylation.
In vivo target sequence preference of METTL4
Since METTL4 catalyzes Am N 6 -methylation in vitro, we next investigated if METTL4 can also do so in vivo by rescuing METTL4 expression in Mettl4-KO cells. Similar to all other known m6A and m6Am writers, exogenous METTL4 mainly localizes to the nucleus though in rare cases, exogenous METTL4 was also found in the cytoplasm ( Figure 3A , S3A). More importantly, overexpressing METTL4 WT rescued the loss of m6Am in U2 snRNA of Mettl4-KO cells ( Figure 3B ). On the other hand, overexpressing METTL4 CD did not result in the same rescue effect, indicating that METTL4 WT is directly catalyzing N 6 -methylation of U2 snRNA Am in vivo ( Figure 3B ). While we had previously described the preferred RNA target for METTL4 catalysis, we envisioned that treating an extensive variety of RNA sequences with METTL4 will provide a clearer picture of its target sequence preference. Fortunately, the overexpression of METTL4 WT in human cells affords such an opportunity: since METTL4 WT is capable of methylating U2 snRNA in vivo, exposing METTL4 WT to the entire human transcriptome allows us to simulate an in vivo methylation assay and determine METTL4's target sequence motif by identifying additional sites of specific RNA methylation. As such, we compared the global methylomes of the METTL4 WTand METTL4 CD -rescue cells to determine if METTL4 also mediates adenosine-N 6 -methylation of other RNAs besides U2 snRNA. This revealed that overexpressing METTL4 WT , but not METTL4 CD , led to the appearance of multiple N 6 -methyl-adenine sites in several mRNAs ( Figure 3C , Table 2 ). Since these sites are absent in WT cells, we denote them as de novo RNA methylation sites ( Figure 3D , S3B). Amongst these de novo methylation sites, we identified the dominant motif sequence to be 'HMAGKD' (Figure 3E , H=A/C/U, M=A/C, K=G/U, D=A/G/U, A is methylation site).
Since the U2 snRNA 'CAm6AmGUG' motif is a subset of the 'HMAGKD', this further validates 'HMAGKD' to be METTL4's target sequence motif.
We next assessed if the presence of a 'HMAGKD' sequence is the sole criterion for de novo methylation by METTL4 WT or if there exists other cis-acting elements and/or trans-acting factors that guide this process. We first speculated if mRNA expression level is one such factor. However, we found that the same mRNA can possess multiple 'HMAGKD' sequences but only have one being de novo methylated, thus ruling out mRNA abundance as a key criterion ( Figure 3F , S3C). We next considered that METTL4 preferred to methylate Am over A, suggesting that all de novo methylated targets initially contained 'HMAmGKD'. As such, we analyzed Am methylomes mapped using Nm-seq but found no overlap between METTL4 WT targeted sites and previously mapped Am sites within the human transcriptome (30) .
However, we do not completely rule out Am presence as a criterion since Am sites mapped by Nm-seq have yet to be fully validated and there could be multiple false negatives (31) . Finally, we assessed if de novo N 6 -methylated adenosine exhibited specific positional patterns along the mRNA length. This revealed a slight preference of METTL4 WT -dependent methylation to be within the CDS ( Figure 3G ). This suggests that cis-acting elements or trans-acting factors associated with the CDS help to guide de novo methylation by METTL4 WT .
METTL4 regulates pre-messenger RNA splicing
While loss of Mettl4 had no appreciable effect on cell growth rate ( Figure S4A ), given the role of U2 in pre-mRNA splicing, we next performed RNA sequencing on WT and Mettl4-KO HEK293T cells to search for splicing changes. By applying a stringent criterion to identify the most reliable splicing changes (see Methods), we found a total of 296 splicing events in 165 genes that change upon KO of Mettl4, with a majority of cassette exons over differential intron retention, and more alternative 3' splice sites than 5' splice sites ( Figure 4A ). Among the total of 214 affected cassette exons, there are 129 (~60%) events with enhanced exclusion, and 85 (40%) with increased inclusion in Mettl4-KO cells ( Figure 4B ). A subset of splicing changes map to unannotated splice sites or exons ( Figure 4C, S4B ). Indeed, we found an excess of unannotated alternative 3' splice sites over unannotated 5' splice sites, while most affected cassette exons are annotated.
Most of the splicing events affected in Mettl4-KO cells had either a high or low
starting splicing level or PSI (percentage spliced in) while events with intermediate PSI were affected in lower numbers ( Figure 4D ). As expected, the affected unannotated splicing events tended to have a low starting PSI ( Figure 4D , upper chart). As shown before, the magnitude of splicing change (∆PSI) was the largest for events with intermediate starting PSI ( Figure 4E ) (32) . We show RT-PCR validation of two representative cassette exons for which Mettl4-KO increases inclusion such as Ogt, or increases exclusion such as Tceal9 ( Figure 4F ).
Last, DAVID analysis revealed that the set of genes with differential alternative splicing events upon Mettl4-KO is enriched in nuclear processes such as DNA repair and RNA binding or processing ( Figure S4C ) (33, 34) . Hence, the enriched categories might just reflect a preponderance of genes encoding splicing factors or related processes that are themselves regulated by alternative splicing (35) .
Features of splicing events affected by Mettl4-KO
Analysis of splice-site strength using the MAXENT algorithm revealed that the annotated cassette exons with increased exclusion in Mettl4-KO have weak 3' splice sites ( Figure 5A ) (36) . The other subcategories in 3' splice sites and all the 5' splicesite analyses showed no statistically significant differences. This included the unannotated 3' splice sites, probably because of the low number of detected splicing events in this group. The exon and intron lengths associated with the splicing events altered in Mettl4-KO showed no statistically significant differences either ( Figure   S4D -S4F).
A more detailed look at the affected 3' splice sites associated with either increased exclusion or inclusion revealed differences in both their polypyrimidine tracts and in the sequence surrounding the AG dinucleotide at the intron-exon junction ( Figure   5B ). Comparison of the 3' splice-site motifs by Jensen-Shanon divergence revealed that the polypyrimidine tract motif for increased inclusion events exhibits two positions (-8 and -12) with a significantly higher incidence of uridines than purines, while other upstream positions have a lower frequency of uridines, albeit not reaching significance ( Figure 5C ). The polypyrimidine tract motif for increased exclusion events did not reveal any position with a significant change ( Figure 5D ). In turn, the motif around the terminal AG dinucleotide did not show significant differences for increased inclusion events ( Figure 5E ) yet for increased exclusion, it revealed a significantly reduced frequency of the consensus G at the first exonic position ( Figure 5F ). Last, motif analyses for 5' splice sites revealed just a depletion of Cs at position -2 for increased exclusion events ( Figure S4G ), which might likely be a spurious hit. Overall, these analyses reveal that the 3' splice sites affected upon Mettl4-KO exhibit distinct characteristics potentially related to the absence of m6Am at position 30 of the U2 snRNA.
Finally, we searched for enriched motifs in the 200-nucleotide intronic fragments flanking the affected splice sites and exons, and found a very clear GGGAGGG consensus motif on both upstream and downstream introns ( Figure 5G ). This motif corresponds to the binding site of hnRNP-H2 protein (37) . There were a few more enriched motifs including C-rich upstream intronic sequences ( Figure S4H ). Overall, the METTL4-dependent splicing events exhibit particular 3' splice-site features possibly linked to U2 snRNA modification, yet other mechanisms mediated by RNA Binding Proteins (RBPs) may also apply.
Discussion
Nucleotide 30 of U2 snRNA is an adenosine known to be ribose-2'O-methylated to give Am (28) . Recently, the same adenosine was also shown to be N 6 -methylated to m6Am but the writer that catalyzes this N 6 -methylation was unknown (20) . Based on a past phylogenetic prediction of METTL4 as a N 6 -methylation writer (29), we knocked out human Mettl4 and sequenced the resulting loss of RNA methylation, thereby confirming that METTL4 is required for N 6 -methylation at adenosine 30 of U2 snRNA. We also used nucleoside HPLC-MS/MS to validate the identity of the resultant modification as m6Am. By overexpressing recombinant METTL4, we demonstrated the necessity of METTL4's catalytic site in its methylation activity and that METTL4 is able to directly methylate U2 snRNA both in vitro and in vivo. N 6 -methylation writers such as METTL3 and PCIF1 have multiple in vivo targets and thus by comparing the difference in precise RNA methylomes before and after depleting these writers in cells, we can determine the in vivo target RNA preference for each writer (27) . METTL4 however, only has 1 clear in vivo target, making such an analysis non-trivial. We circumvented this limitation by overexpressing either METTL4 WT or METTL4 CD in HEK293T cells to simulate an in vivo methylation assay.
Comparing differences between the RNA methylomes in the 2 overexpressed cells revealed METTL4 WT -dependent de novo methylation sites, allowing us to determine METTL4's in vivo target preference to be 'HMAGKD'. We note that presence of the 'HMAGKD' sequence alone does not guarantee in vivo de novo methylation by METTL4. This indicates that other cis-acting elements, such as RNA secondary structure or Am presence, or trans-acting factors, such as METTL4 co-factors help to guide this process. During the preparation of this manuscript, another study also reported METTL4 as a U2 snRNA m6Am writer (38) but due to a lack of m6Amsequencing, could not conduct the extensive in vivo target RNA preference analysis of our study. Therefore, our findings will facilitate further studies on how METTL4 specifically targets U2 snRNA.
As opposed to U2 pseudouridines, which in yeast were shown to affect either U2 snRNP biogenesis, particle stability, splicing function and even growth phenotypes In human major spliceosome introns (>99% of all introns), 3' splice sites are recognized by the pre-formed and stable U2 Auxiliary Factor (U2AF) heterodimer, in which the large U2AF65 subunit binds to the polypyrimidine tract while the small U2AF35 subunit binds a sequence motif around the intron-terminal AG dinucleotide (41) (42) (43) (44) (45) (46) . Similar to other splicing signals, 3' splice sites are highly heterogeneous in humans. Hence, the relative contribution of the two subunits to 3' splice-site recognition is highly variable. This had previously led to the model of AG-dependent versus AG-independent introns, as the latter introns have long polypyrimidine tracts that make U2AF35 binding dispensable for 3' splice-site recognition (47) . U2AF binding to 3' splice sites together with Splicing Factor 1 (SF1) to the Branch Point Sequence (BPS) then recruits the U2 snRNP in an ATP-dependent manner to displace SF1, such that U2 snRNA base pairs to the BPS and bulges out an A to perform the first transesterification step of splicing (48, 49) . As the U2-30 position is not in the BPS recognition sequence yet 5'-adjacent to it, we hypothesize that the m6Am modification may affect the recruitment of U2 snRNP by U2AF in different manners depending on the pre-mRNA substrate, thereby affecting the overall splicing patterns in a subtle manner. Further studies should aim to identify the mechanistic details of splicing events affected by METTL4 depletion, likely by in vitro splicing reactions with reconstituted U2 snRNP particles without and with U2 snRNA position 30 m6Am modification, so as to derive the respective U2 interactomes, degree of U2 association with pre-mRNAs, and efficiency of spliceosome formation.
Furthermore, the enrichment of GGGAGGG motif in both flanking introns of several METLL4-dependent splicing events suggests that some such events might be regulated by the cognate RBP that recognizes this motif, which is hnRNP-H2 (50).
This RBP did not undergo any major expression or splicing change at RNA level upon Mettl4 KO (data not shown), so if this factor accounts for a fraction of splicing events, it is regulated by translation efficiency or post-translational modifications.
Further studies should address the connection between METLL4 and hnRNP-H2.
Our work here on the discovery of METTL4 as a U2 m6Am writer provides a framework to explain how METTL4 regulates pre-mRNA splicing, thereby proposing a new pathway for epitranscriptomic modifications to regulate RNA processing.
Methods
m6ACE-seq
m6ACE-seq libraries were constructed as previously described (27) Finally, primer-dimer and adapter-dimers were removed with Ampure XP beads before undergoing PE75 sequencing on the Illumina Nextseq platform.
m6ACE-seq analysis
m6ACE-seq analysis was performed as previously described (27) : Fastq sequences were first filtered for a quality score of 20, then trimmed of 5' and 3' adapter sequences and poly(A) tails using Cutadapt (53) . The 8-mer UMI located at the first 8 nucleotides of read 1 was registered and trimmed. Any complementary UMI sequence in read 2 was also trimmed. Reads were mapped to the methylated spike-in (Table 1) using Bowtie2, or to the hg38 assembly transcriptome (Gencode v28 comprehensive gene annotations) using STAR (54, 55) . Aligned pairs that had the same mapping coordinates and UMIs were filtered out as PCR duplicates. Read-start coordinates in hg38-mapped reads that began with an adenosine nucleotide, and had a minimum mean read count of 1 across the triplicate samples were collated. m6A or m6Am sites were identified as read starts that were at least 2-fold enriched in 
RNAseq Splicing Analysis
WT and Mettl4-KO HEK293T RNAseq libraries were first processed using CutAdapt to remove adaptors and to trim all reads to a uniform length of 101bp for compatibility with downstream analysis steps. Read alignment to the genome was then performed using STAR (2.7.0a) in two-pass mode using the hg38 genome assembly and GENCODE v28 gene annotations (55) .
Alternative splicing differences were analysed by an in-house pipeline using replicate MATS (rMATS 3.2.5) and filtered based on cut-offs of FDR ≤ 0.05, an absolute change in percent spliced in (|ΔPSI|) ≥ 0.1 (58, 59) . In addition, events with mean sample junction counts (IC_Sample + SC_Sample) < 20 were filtered out to reduce false positives arising from transcript dropout in low abundance isoforms. The validation of several differential alternative splicing events were performed using an RT-PCR assay (36, 59) .
Additional exon-level features were added to the data using databases constructed from the UCSC Table Browser , as well as in-house R scripts. Splice-site strengths were calculated using MaxEntScan (36) . Comparisons were made between the exon features of the differentially spliced cassette exons and a transcriptome-wide background based on all known human internal exons. Cut-offs of 500nt and 30,000nt were applied on the exon and intron length datasets respectively to reduce data skewing caused by extreme outliers. Splice site strength values below 0 were also discarded from the analysis for similar reasons. The statistical significance of feature differences were calculated using Welch's t-test and p-values were adjusted using Bonferroni correction when necessary.
The Jensen-Shannon Divergences of splice site sequence subsets and associated tests for statistical significance were calculated using DiffLogo (60) . All other sequence logos were generated using ggseqlogo (61) . The cassette exon sequences, as well as up to 200nt stretches up-and downstream of the exon (excluding the splice sites), were scanned for strand-specific 6-10nt motifs using MEME (37) . The sequences generated by MEME were then fed into TOMTOM to search for RNA binding proteins with similar binding motifs. Functional annotation of the genes containing differentially spliced cassette exons was performed using DAVID (33, 34) . (E) Plot of initial PSI against the absolute changes in PSI values, divided into four equal X-axis intervals and annotated with the mean change in PSI per interval.
RT-PCR assay
(F) RT-PCR validations of two differential alternative splicing events for cassette exons in Ogt and Tceal9 genes. The RNA-seq PSI is aligned to the RT-PCR results in agarose gels with its corresponding PSI. The identity of splicing products by exon inclusion or exclusion is schematically shown next to the gels. 
